INS and diabetes mellitus: Among patients with DM under treatment, either alone or in combination, the majority (92.3%) were on metformin, 23.1% insulin, 15.4% sodium glucose cotransporter-2 (SGLT2) inhibitors, 15.4% dipeptidyl peptidase-4 (DPP-4) inhibitors, 7.7% glucagon-like peptide-1 (GLP-1) agonists and 7.7% glitazones.